1-12 of 12
Judith A. Fox
Close
Sort by
Journal Articles

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, Sascha Endres, Philipp M. Roessner, Felix Seyfried, Claudia Walliser, Martin Wist, Jialei Qi, Eugen Tausch, Daniel Mertens, Judith A. Fox, Klaus-Michael Debatin, Lüder Hinrich Meyer, Pietro Taverna, Martina Seiffert, Peter Gierschik, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 139 (6): 859–875.
https://doi.org/10.1182/blood.2021011516
Published: 2022
Includes: Supplemental data
Journal Articles

Efficacy of Vecabrutinib Treatment in a Murine Model of Sclerodermatous Graft-Versus-Host-Disease

Kamira Maharaj, Melanie Mediavilla-Varela, Angimar Uriepero, Judith A. Fox, Pietro Taverna, Wael Gamal, Eva Sahakian, Javier Pinilla Ibarz
Journal: Blood
Blood (2021) 138 (Supplement 1): 1685.
https://doi.org/10.1182/blood-2021-150598
Published: 2021
Journal Articles

Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib

Mohamad M. Adada, Reona Sakemura, Michelle J. Cox, Caludia Manriquez-Roman, Elizabeth L. Siegler, Erin E. Tapper, Carli M. Stewart, Kendall J. Schick, Ismail Can, Ekene J. Ogbodo, Evandro D. Bezerra, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Pietro Taverna, Judith A. Fox, Gloria Olivier, Susan L. Slager, Wei Ding, Sameer A. Parikh, Neil E. Kay, Saad S. Kenderian
Journal: Blood
Blood (2021) 138 (Supplement 1): 906.
https://doi.org/10.1182/blood-2021-151073
Published: 2021
Journal Articles

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

John N. Allan, MD, Krish Patel, MD, Anthony R. Mato, MDMSCE, William G. Wierda, MD PhD, Javier Pinilla Ibarz, MD PhD, Michael Y. Choi, MD, Susan M. O'Brien, MD, Jeff P. Sharman, MD, Mazyar Shadman, MD, Douglas E Gladstone, MD, Matthew S. Davids, MD, John M. Pagel, MD PhD DSc, Renee Ward, MD PhD, Gary Acton, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3041.
https://doi.org/10.1182/blood-2019-126286
Published: 2019
Journal Articles

Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies

John N. Allan, MD, William G. Wierda, MD PhD, Krish Patel, MD, Susan M. O'Brien, MD, Anthony R Mato, MD, Matthew S Davids, Richard R. Furman, MD, John M. Pagel, MD PhD, Judith A. Fox, PhD, Renee Ward, MD PhD, Pietro Taverna, PhD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3141.
https://doi.org/10.1182/blood-2018-99-116382
Published: 2018
Journal Articles

AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia

Linda G Eissenberg, PhD, Julie Ritchey, Michael P. Rettig, PhD, Judith A. Fox, PhD, Jeanmarie Guenot, PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2727.
https://doi.org/10.1182/blood-2018-99-118573
Published: 2018
Journal Articles

High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group

Anne Quinquenel, Luc Matthieu Fornecker, Remi Letestu, Carole Fleury, Loic Ysebaert, MD PhD, Marie-Sarah Dilhuydy, MD, Romain Guieze, MD, Pierre Feugier, Damien Roos-Weil, MD, Lise Willems, MD, Anne-Sophie Michallet, MD PhD, Alain Jacques Delmer, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Vincent Levy, MD PhD, Florence Cymbalista, MD, Fanny Baran-Marszak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 584.
https://doi.org/10.1182/blood-2018-99-114027
Published: 2018
Journal Articles

Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, Eugen Tausch, MD, Judith A. Fox, PhD, Pietro Taverna, PhD, Stephan Stilgenbauer
Journal: Blood
Blood (2018) 132 (Supplement 1): 1868.
https://doi.org/10.1182/blood-2018-99-116664
Published: 2018
Journal Articles

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

Linda L. Neuman, MD MBA, Renee Ward, MD PhD, David Arnold, Daniel L. Combs, BS, Deena Gruver, MS, Wendy Hill, MBA, Josué Mfopou Kunjom, MD PhD, Langdon L. Miller, MD, Judith A. Fox, PhD
Journal: Blood
Blood (2016) 128 (22): 2032.
https://doi.org/10.1182/blood.V128.22.2032.2032
Published: 2016
Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Farhad Ravandi, MD, Ellen Ritchie, MD, Hamid Sayar, MD, Jeffrey Lancet, MD, Michael D. Craig, MD, Norbert Vey, MD, Stephen A. Strickland, MD, Gary Schiller, MD, Elias Jabbour, MD, Harry P. Erba, MD PhD, Arnaud Pigneux, MD, Heinz-August Horst, MD, Christian Recher, MD, Virginia M. Klimek, MD, Jorge Cortes, MD, Eric J. Feldman, MD, Adam R. Craig, MD PhD, Judith A. Fox, PhD, Renee Ward, MD PhD, Jennifer Smith, PhD, Gary Acton, MD, Cyrus Mehta, PhD, Hagop M. Kantarjian, MD, Robert K Stuart, MD
Journal: Blood
Blood (2014) 124 (21): LBA-6.
https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6
Published: 2014
Journal Articles

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

Rong Chen, William G. Wierda, Sherri Chubb, Rachael E. Hawtin, Judith A. Fox, Michael J. Keating, Varsha Gandhi, William Plunkett
Journal: Blood
Blood (2009) 113 (19): 4637–4645.
https://doi.org/10.1182/blood-2008-12-190256
Published: 2009
Journal Articles

Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol.

Rong Chen, William G. Wierda, Sherri Benaissa, Ute Hoch, Rachael E. Hawtin, Judith A. Fox, Michael J. Keating, Varsha Gandhi, William Plunkett
Journal: Blood
Blood (2007) 110 (11): 3112.
https://doi.org/10.1182/blood.V110.11.3112.3112
Published: 2007